Items tagged with Latent TB
Drug for latent TB is of no use here: Doctors (post)
Hyderabad: Diagnosis of latent tuberculosis is not a priority in India and the decision of Central Drugs Standard Control Organisation (CDSCO) to import Refapentine drug to treat it is being viewed cynically.
No active TB detected in HSCT patients in Mexico, study finds (post)
Immunocompromised patients who have received a hematopoietic stem cell transplant (HSCT) have an incidence of active tuberculosis infection that is 10 to 40 times higher than the general population. The elevated risk is also accompanied by higher rates of morbidity and mortality.
CROI 2019: New study is a breakthrough for preventing TB in people living with HIV (post)
Geneva – A Unitaid-funded study has found that 3HP, a new, shorter preventive therapy for tuberculosis, is safe for people who also take the HIV drug dolutegravir. The results mark a critical milestone for countries and funding partners seeking to expand preventive TB therapy.
Promising diagnostics for detecting latent TB revealed (post)
A collaboration between the National Center for Supercomputing Applications (NCSA) at the University of Illinois, Mayo Clinic, and the University of Michigan are introducing a new machine-learning-driven approach to latent tuberculosis infections (LTBI) diagnostics. While leveraging a high throughput detection technology and powerful bioinformatics, this approach aims to reveal multi-marker signatures for LTBI diagnosis and risk stratification.
Controlling latent TB infection in high-burden countries: A neglected strategy to end TB (post)
A perspective published in PLOS Medicine provides the justification for scaling up TB preventive therapy in high-burden countries.
Latent TB detection: QuantiFERON-TB Gold Plus vs QuantiFERON-TB Gold In-Tube (post)
DALLAS — Positive results with respect to the presence of latent tuberculosis infection (LTBI) in patients with renal failure were more consistent with the use of QuantiFERON-TB Gold Plus (QFT-G plus) testing compared with the use of QuantiFERON-TB Gold In-Tube (QFT-GIT) testing.
Responsible use of rifampin for the treatment of latent TB infection (post)
A commentary published in the Canadian Medical Association Journal emphasized the importance of the responsible use of rifampin for the treatment of latent TB. "As rifampin is the most important drug for the treatment of active TB, the development of rifampin resistance carries serious consequences to patients and society."
Fourth generation QuantiFERON-TB Gold noninferior to previous in immunocompromised (post)
In patients who are immunocompromised, such as people living with HIV, the new fourth-generation QuantiFERON-TB Gold Plus (QFT-Plus) assay demonstrated similar sensitivity to the third-generation interferon-gamma release assay for the diagnosis of latent tuberculosis (TB), according to study results presented at American Society of Microbiology (ASM) Microbe 2019, held June 20 to 24 in San Francisco, California.
Update of WHO guidelines on the management of latent TB infection (post)
01 July 2019 | Geneva: In July 2019, the World Health Organization (WHO) will convene a Guideline Development Group (GDG) to discuss what updates are needed to the current guidelines for programmatic management of latent tuberculosis infection (LTBI).
The fight against TB: researchers at St. Michael’s Hospital identify best practices for the use of antibiotics (post)
Toronto, Canada , July 4, 2019 - Tuberculosis (TB) could develop resistance to rifampin – a crucial antibiotic – if clinicians aren’t vigilant about properly assessing patients for the active form of disease, suggests a paper written by St. Michael’s Hospital scientists and published in the Canadian Medical Association Journal.
Page 7 of 13 · Total posts: 0
←First 6 7 8 Last→